HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+15.38%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.47B
AUM Growth
+$2.47B
(-0.06%)
Cap. Flow
-$200M
Cap. Flow
% of AUM
-8.1%
Top 10 Holdings %
Top 10 Hldgs %
46.45%
Holding
67
New
25
Increased
7
Reduced
17
Closed
14
Top Buys
| 1 |
Maravai LifeSciences
MRVI
|
$87.9M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
$81.7M |
| 3 |
Hologic
HOLX
|
$74.1M |
| 4 |
McKesson
MCK
|
$73.5M |
| 5 |
Bristol-Myers Squibb
BMY
|
$72.7M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$118M |
| 2 |
Zimmer Biomet
ZBH
|
$116M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$107M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
$99.5M |
| 5 |
Medtronic
MDT
|
$93.5M |
Sector Composition
| 1 | Healthcare | 96.62% |
| 2 | Real Estate | 3.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $155M | 5.98% | 2,118,090 +327,780 | +18% | +$24M |
|
2
IQVIA
IQV
$32.4B
| $144M | 5.55% | 803,310 -37,430 | -4% | -$6.71M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $138M | 5.32% | 583,290 +220,900 | +61% | +$52.2M |
|
4
Cooper Companies
COO
$13.4B
| $126M | 4.84% | 345,630 +104,090 | +43% | +$37.8M |
|
5
HCA Healthcare
HCA
$94.5B
| $117M | 4.51% | 711,240 -215,070 | -23% | -$35.4M |
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $100M | 3.87% | 902,601 -227,347 | -20% | -$25.3M |
|
7
Aurinia Pharmaceuticals
AUPH
$1.58B
| $95.9M | 3.7% | 6,937,448 -1,936,505 | -22% | -$26.8M |
|
8
AbbVie
ABBV
$372B
| $91.5M | 3.53% | 853,650 -465,250 | -35% | -$49.9M |
|
9
Humana
HUM
$36.5B
| $90.3M | 3.48% | 220,181 -8,749 | -4% | -$3.59M |
|
|
10
Maravai LifeSciences
MRVI
$350M
| $87.9M | 3.39% | +3,134,712 | New | +$87.9M |
|
|
11
Zimmer Biomet
ZBH
$21B
| $85M | 3.28% | 551,384 -754,786 | -58% | -$116M |
|
|
12
Bio-Rad Laboratories Class A
BIO
$8.06B
| $81.7M | 3.15% | +140,080 | New | +$81.7M |
|
|
13
Bristol-Myers Squibb
BMY
$96B
| $80.5M | 3.1% | 1,297,700 +1,172,200 | +934% | +$72.7M |
|
|
14
Hologic
HOLX
$14.9B
| $74.1M | 2.86% | +1,017,280 | New | +$74.1M |
|
|
15
McKesson
MCK
$85.4B
| $73.5M | 2.84% | +422,800 | New | +$73.5M |
|
|
16
Medtronic
MDT
$119B
| $70.8M | 2.73% | 604,150 -798,010 | -57% | -$93.5M |
|
17
Guardant Health
GH
$8.41B
| $70M | 2.7% | 543,160 -254,570 | -32% | -$32.8M |
|
18
Johnson & Johnson
JNJ
$427B
| $68.5M | 2.64% | +435,010 | New | +$68.5M |
|
19
Haemonetics
HAE
$2.63B
| $67.3M | 2.59% | +566,370 | New | +$67.3M |
|
20
Royalty Pharma
RPRX
$15.6B
| $67M | 2.59% | 1,339,530 -156,880 | -10% | -$7.85M |
|
|
21
UnitedHealth
UNH
$281B
| $61.4M | 2.37% | 174,990 -336,380 | -66% | -$118M |
|
|
SYNH
22
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $54M | 2.08% | +793,320 | New | +$54M |
|
23
Agios Pharmaceuticals
AGIO
$2.19B
| $43.2M | 1.67% | +997,070 | New | +$43.2M |
|
24
LivaNova
LIVN
$3.08B
| $40.8M | 1.57% | +616,030 | New | +$40.8M |
|
25
Envista
NVST
$3.52B
| $35.1M | 1.35% | +1,039,290 | New | +$35.1M |
|